Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28504523 | 0.76 | USP30 (0.34) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL14745854 | 0.74 | F11 (0.35) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL30831491 | 0.74 | F11 (0.35) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL8992350 | 0.73 | DGAT1 (0.46) | — | |
| SCHEMBL15230171 | 0.72 | KDM4E (0.33) | — | |
| SCHEMBL16238349 | 0.70 | F11 (0.36) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL11940152 | 0.69 | KDM4E (0.39) | — | |
| SCHEMBL28509577 | 0.69 | NNMT (0.33) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL14745974 | 0.68 | KDM4E (0.38) | F2F11PRSS1PRSS2PRSS3 | |
| SCHEMBL28811732 | 0.67 | DGAT1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-114456175-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109348715-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2021-12-31 | — | — | CN | disclosed |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-08-01 | — | — | US | disclosed |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-05-16 | — | — | US | disclosed |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233426-A1 | IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, BMI1 | F2 4142/4885F11 4198/4885PRSS1 2145/4885 |
| US-10220036-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | F2 3573/4885F11 3774/4885PRSS1 1150/4885 |
| US-10676479-B2 | Imidazolepyridine compounds and uses thereof | EZH2, DOT1L, BMI1 | F2 4142/4885F11 4198/4885PRSS1 2145/4885 |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | F2 3573/4885F11 3774/4885PRSS1 1150/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | F2 3573/4885F11 3774/4885PRSS1 1150/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | F2 3573/4885F11 3774/4885PRSS1 1150/4885 |
| US-20190142837-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | F2 3573/4885F11 3774/4885PRSS1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.